


Product Name : Enerisant hydrochloride
Cat. No. : PC-72277
CAS No. : 1152749-07-9
Molecular Formula : C₂₂H₃₁ClN₄O₃
Molecular Weight : 434.965
Target : Histamine Receptor
Solubility : 10 mM in DMSO



Biological Activity

Enerisant hydrochloride (TS091 hydrochloride) is a potent, selective **histamine H3 receptor** antagonist/inverse agonist with IC₅₀ of 2.89 and 14.5 nM against hH3R and rH3R, respectively.

Enerisant inhibited R- α -methylhistamine-stimulated [35S]GTP γ S binding to human histamine H3 receptor and rat histamine H3 receptor with IC₅₀ values of 1.06 and 10.05 nM, respectively, inhibited basal [35S]GTP γ S binding to human histamine H3 receptor with an EC₅₀ value of 0.357 nM.

Enerisant displays negligible effects on binding to human histamine H1, H2, and H4 receptor subtypes, as well as negligible affinities for 66 other receptors, transporters, and ion channels at 1-10 μ M.

Oral administration of enerisant hydrochloride attenuated the dipsogenia response on R- α -methylhistamine-induced dipsogenia in rats, the intraperitoneal administration of enerisant hydrochloride increased the total extracellular acetylcholine levels in the mPFC.

Enerisant hydrochloride significantly decreased slow-wave deep sleep at doses of 1-10 mg/kg (P < 0.01-0.05). Enerisant hydrochloride (1, 3 and 10 mg/kg, p.o.) did not affect the accumulated locomotor activity time at up to 7 hours after administration.

References

Noriko Hino, et al. *J Pharmacol Exp Ther.* 2020 Nov;375(2):276-285.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com